ENXTBR:ARGXBiotechs
What argenx (ENXTBR:ARGX)'s Priority FDA Review for VYVGART in Seronegative gMG Means for Shareholders
argenx SE recently announced that the FDA has accepted for priority review a supplemental Biologics License Application for VYVGART to treat adults with acetylcholine receptor antibody seronegative generalized myasthenia gravis, supported by Phase 3 ADAPT SERON data showing statistically significant improvements in daily living scores versus placebo.
This priority review, with a PDUFA action date set for May 10, 2026, could materially broaden VYVGART’s reach across previously underserved...